欢迎来到OAJRC平台！

期刊栏目

投稿

审稿

期刊目次

加入编委

期刊订阅

添加您的邮件地址以接收即将发行期刊数据：

当前位置：国际医药研究前沿 > 2018年 2卷 (1)期

Open Access Article

International Medical Research Frontier. 2018; 2: (1) 2; - ; DOI: DOI:10.12208/j.imrf.20180002.

Progression of multi-omics research in gliomas
神经胶质瘤多组学研究进展

作者： 杨海燕, 詹显全 *

中南大学湘雅医院卫生部肿瘤蛋白质组学重点实验室、结构生物学与药物设计、湖南省工程实验室、抗癌药物国家地方联合工程实验室 (长沙，410008)

*通讯作者：詹显全,单位：中南大学湘雅医院卫生部肿瘤蛋白质组学重点实验室、结构生物学与药物设计、湖南省工程实验室、抗癌药物国家地方联合工程实验室 (长沙，0008)；

国家自然科学基金国家高技术“863计划”子项目湖南省自然科学基金湖南省百人计划基金（詹显全）湘雅医院人才引进基金（詹显全）

发布时间: 2018-09-10 总浏览量: 5333

PDF 全文下载引用本文收录截图（CNKI-Scholar）

摘要

神经胶质瘤作为最常见的原发中枢神经系统肿瘤，具有很大的异质性。越来越多的研究表明，神经胶质瘤是一个多基因、多蛋白质参与的多阶段发展的疾病，并与基因组、转录组、蛋白质组及表观遗传组的异常关系密切。不同组学的研究给神经胶质瘤研究注入了系统的视角，各个组学之间并非相互孤立或单项流动，具有相互作用及双向及多向流动的特点。本文对神经胶质瘤多组学研究的进展进行综述。

关键词： 神经胶质瘤，基因组学，转录组学，蛋白质组学

Abstract

Glioma, as one of the most common primary tumors in central nervous system, has a great heterogeneity. More and more studies have shown that glioma is a multigene- and multiprotein-involved multi-stage developed disease, and is closely related to genome, transcriptome, proteome and epigenetic abnormalities. Different omics studies have provided a systematic perspective into the research of glioma, and each omics is not isolated or single-flowing. That is to say, they have the characteristics with close relationship and two-way or multi-directional flow by each other. This article comprehensively reviews the progress of multi-omics research in gliomas.

Key words： Glioma，genomics，transcriptomics，proteomics

参考文献 References

[1] Chen J, McKay RM, Parada LF. Malignant glioma: lessons from genomics, mouse models, and stem cells.Cell,2012 149 (1) : 36-47.

[2] Yu X, Sun NR, Jang HT, Guo SW, Lian MX. Associations between EGFR gene polymorphisms and susceptibility to glioma: a systematic review and meta-analysis from GWAS and case-control studies.Oncotarget,2017 8 (49) : 86877-86885.

[3] Wu Q, Peng Y, Zhao X. An Updated and Comprehensive Meta-Analysis of Association Between Seven Hot Loci Polymorphisms from Eight GWAS and Glioma Risk.Mol Neurobiol,2016 53 (7) : 4397-4405.

[4] Yung WK. From GWAS risk foci to glioma molecular subclass.Neuro-oncology,2013 15 (5) : 513-514.

[5] Rood BR, MacDonald TJ. Pediatric high-grade glioma: molecular genetic clues for innovative therapeutic approaches.J Neuro-oncol,2005 75 (3) : 267-272.

[6] Isolan GR, Ribas Filho JM, Isolan PM, Giovanini A, Malafaia O, Dini LI, Kummer A, Jr, Negrao AW. Astrocytic neoplasms and correlation with mutate p53 and Ki-67 proteins.Arquivos de Neuro-psiquiatria,2005 63 (4) : 997-1004.

[7] Wang YY, Zhang T, Li SW, Qian TY, Fan X, Peng XX, Ma J, Wang L, Jiang T. Mapping p53 mutations in low-grade glioma: a voxel-based neuroimaging analysis.Am J Neuroradiol,2015 36 (1) : 70-76.

[8] Panciani PP, Giordana MT, Gallone S, Muratori A, Rotunno R, Migliorati K, Spena G, Ducati A, Fontanella M. Blood-tissue analysis of TP53 polymorphisms and survival of patients with glioma.J Neurosurg Sci,2018 36 (1) : 70-76.

[9] Egan KM, Nabors LB, Olson JJ, Monteiro AN, Browning JE, Madden MH, Thompson RC. Rare TP53 genetic variant associated with glioma risk and outcome.J Med Genet,2012 49 (7) : 420-421.

[10] Zhang X, Tian Q, Wang L, Liu Y, Li B, Liang Z, Gao P, Zheng K, Zhao B, Lu H. Radiomics Strategy for Molecular Subtype Stratification of Lower-Grade Glioma: Detecting IDH and TP53 Mutations Based on Multimodal MRI.J Magnetic Resonance Imaging,2018 .

[11] Sarma PP, Dutta D, Mirza Z, Saikia KK, Baishya BK. Point mutations in the DNA binding domain of p53 contribute to glioma progression and poor prognosis.Molekuliarnaia Biologiia,2017 51 (2) : 334-341.

[12] Byeon SJ, Myung JK, Kim SH, Kim SK, Phi JH, Park SH. Distinct genetic alterations in pediatric glioblastomas.Child's Nervous System,2012 28 (7) : 1025-1032.

[13] Cheng Y, Ng HK, Zhang SF, Ding M, Pang JC, Zheng J, Poon WS. Genetic alterations in pediatric high-grade astrocytomas.Human Pathol,1999 30 (11) : 1284-1290.

[14] Xiao WZ, Han DH, Wang F, Wang YQ, Zhu YH, Wu YF, Liu NT, Sun JY. Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis.Tumour Biol,2014 35 (7) : 6687-6693.

[15] Han F, Hu R, Yang H, Liu J, Sui J, Xiang X, Wang F, Chu L, Song S. PTEN gene mutations correlate to poor prognosis in glioma patients: a meta-analysis.Oncotargets,Ther 2016 9 : 3485-3492.

[16] Preusser M, Haberler C, Hainfellner JA. Malignant glioma: neuropathology and neurobiology.Wiener Medizinische Wochenschrift,2006 156 (11-12) : 332-337.

[17] Hulleman E, Helin K. Molecular mechanisms in gliomagenesis.Adv Cancer Res,2005 94 : 1-27.

[18] Kondo T. Molecular mechanisms involved in gliomagenesis.Brain Tumor Pathol,2017 34 (1) : 1-7.

[19] Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.Cancer Discovery,2012 2 (5) : 458-471.

[20] Yuan Y, Qi C, Maling G, Xiang W, Yanhui L, Ruofei L, Yunhe M, Jiewen L, Qing M. TERT mutation in glioma: Frequency, prognosis and risk.J Clin Neurosci,2016 26 : 57-62.

[21] Zhang Z, Chan AK, Ding X, Li Y, Zhang R, Chen L, Liu Y, Wang Y, Xiong J, Ng HK, et al. Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas.Neuro-Oncol,2017 19 (7) : 1008-1010.

[22] Vuong HG, Altibi AMA, Duong UNP, Ngo HTT, Pham TQ, Chan AK, Park CK, Fung KM, Hassell L. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.Crit Rev Oncol/Hematol,2017 120 : 1-9.

[23] Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al. An integrated genomic analysis of human glioblastoma multiforme.Science,2008 321 (5897) : 1807-1812.

[24] Neal A, Kwan P, O'Brien TJ, Buckland ME, Gonzales M, Morokoff A. IDH1 and IDH2 mutations in postoperative diffuse glioma-associated epilepsy.Epilepsy Behavior,2018 78 : 30-36.

[25] Whittle IR, Short DM, Deighton RF, Kerr LE, Smith C, McCulloch J. Proteomic analysis of gliomas.British J Neurosurg,2007 21 (6) : 576-582.

[26] Niclou SP, Fack F, Rajcevic U. Glioma proteomics: status and perspectives.J Proteomics,2010 73 (10) : 1823-1838.

[27] Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, Duijm JE, Daemen A, Bleeker FE, Bralten LB, Kloosterhof NK, et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.Cancer Res,2009 69 (23) : 9065-9072.

[28] Tso CL, Freije WA, Day A, Chen Z, Merriman B, Perlina A, Lee Y, Dia EQ, Yoshimoto K, Mischel PS, et al. Distinct transcription profiles of primary and secondary glioblastoma subgroups.Cancer Res,2006 66 (1) : 159-167.

[29] Vital AL, Tabernero MD, Castrillo A, Rebelo O, Tao H, Gomes F, Nieto AB, Resende Oliveira C, Lopes MC, Orfao A. Gene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology.Neuro-Oncol,2010 12 (9) : 991-1003.

[30] Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.Cancer Cell,2006 9 (3) : 157-173.

[31] Faury D, Nantel A, Dunn SE, Guiot MC, Haque T, Hauser P, Garami M, Bognar L, Hanzely Z, Liberski PP, et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors .J Clin Oncol ,2007 25 (10 ) : 1196 -1208 .

[32] Shirahata M, Iwao-Koizumi K, Saito S, Ueno N, Oda M, Hashimoto N, Takahashi JA, Kato K. Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis.Clin Cancer Res,2007 13 (24) : 7341-7356.

[33] Frattini V, Pagnotta SM, Tala, Fan JJ, Russo MV, Lee SB, Garofano L, Zhang J, Shi P, Lewis G, et al. A metabolic function of FGFR3-TACC3 gene fusions in cancer.Nature,2018 553 (7687) : 222-227.

[34] Khalil AA. Biomarker discovery: a proteomic approach for brain cancer profiling.Cancer Science,2007 98 (2) : 201-213.

[35] Collet B, Guitton N, Saikali S, Avril T, Pineau C, Hamlat A, Mosser J, Quillien V. Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach.Proteome,Sci 2011 9 (1) : 16.

[36] Li J, Zhuang Z, Okamoto H, Vortmeyer AO, Park DM, Furuta M, Lee YS, Oldfield EH, Zeng W, Weil RJ. Proteomic profiling distinguishes astrocytomas and identifies differential tumor markers.Neurology,2006 66 (5) : 733-736.

[37] Schwartz SA, Weil RJ, Johnson MD, Toms SA, Caprioli RM. Protein profiling in brain tumors using mass spectrometry: feasibility of a new technique for the analysis of protein expression.Clin Cancer Res,2004 10 (3) : 981-987.

[38] Schwartz SA, Weil RJ, Thompson RC, Shyr Y, Moore JH, Toms SA, Johnson MD, Caprioli RM. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry.Cancer Res,2005 65 (17) : 7674-7681.

[39] Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, Holland E. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations.PloS One,2009 4 (11) : 7752.

[40] Choi JD, Lee JS. Interplay between Epigenetics and Genetics in Cancer.Genomics Informatics,2013 11 (4) : 164-173.

[41] You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin?.Cancer Cell,2012 22 (1) : 9-20.

[42] Liao P, Ostrom QT, Stetson L, Barnholtz-Sloan JS. Models of Epigenetic Age Capture Patterns of DNA Methylation in Glioma Associated with Molecular Subtype, Survival, and Recurrence.Neuro-Oncol,2018 Feb 8 : .

[43] Silber JR, Bobola MS, Blank A, Chamberlain MC. O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems.Biochimica Biophysica Acta,2012 1826 (1) : 71-82.

[44] Quintavalle C, Mangani D, Roscigno G, Romano G, Diaz-Lagares A, Iaboni M, Donnarumma E, Fiore D, De Marinis P, Soini Y, et al. MiR-221/222 target the DNA methyltransferase MGMT in glioma cells.PloS One,2013 8 (9) : 74466.

[45] Kreth S, Thon N, Eigenbrod S, Lutz J, Ledderose C, Egensperger R, Tonn JC, Kretzschmar HA, Hinske LC, Kreth FW. O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.PloS One,2011 6 (2) : 17156.

[46] Castelo-Branco P, Choufani S, Mack S, Gallagher D, Zhang C, Lipman T, Zhukova N, Walker EJ, Martin D, Merino D, et al. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.Lancet Oncol,2013 14 (6) : 534-542.

[47] Ying Z, Li Y, Wu J, Zhu X, Yang Y, Tian H, Li W, Hu B, Cheng SY, Li M. Loss of miR-204 expression enhances glioma migration and stem cell-like phenotype.Cancer Res,2013 73 (2) : 990-999.

[48] Podlevsky JD, Chen JJ. Evolutionary perspectives of telomerase RNA structure and function.RNA Biol,2016 13 (8) : 720-732.

[49] Wang Y, Zhou Z, Luo H, Wu Z, Geng J, Miu W, Pu Y, Liu N, You Y, Yang Z. Combination of tamoxifen and antisense human telomerase RNA inhibits glioma cell proliferation and anti-apoptosis via suppression of telomerase activity.Mol Med Rep,2010 3 (6) : 935-940.

[50] Sampl S, Pramhas S, Stern C, Preusser M, Marosi C, Holzmann K. Expression of telomeres in astrocytoma WHO grade 2 to 4: TERRA level correlates with telomere length, telomerase activity, and advanced clinical grade.Translational Oncol,2012 5 (1) : 56-65.

[51] Shi Y, Wang Y, Luan W, Wang P, Tao T, Zhang J, Qian J, Liu N, You Y. Long non-coding RNA H19 promotes glioma cell invasion by deriving miR-675.PloS One,2014 9 (1) : 86295.

引用本文

杨海燕, 詹显全, 神经胶质瘤多组学研究进展[J]. 国际医药研究前沿, 2018; 2: (1) : -.

入驻平台

回到首页

搜索文章: